Loading patent…
OwnerOlivier Schwartz, Florence Buseyne +4inventors
InventorsOlivier Schwartz, Florence Buseyne, Delphine Marsac, Marie-Louise Michel, Yves Riviere, Jean-Michel Heard
Estimating the term…
Dendritic cells and macrophages can process extracellular antigens for presentation by MHC-I molecules. HIV-1 epitopes derived from incoming virions are presented through the exogenous MHC-I pathway in primary human dendritic cells, and to a lower extent in macrophages, leading to cytotoxic T lymphocyte activation in the absence of viral protein neosynthesis. Exogenous antigen presentation required adequate virus-receptor interactions and fusion of viral and cellular membranes. These results provide new insights about how anti-HIV cytotoxic T lymphocytes can be activated and are useful for anti-HIV vaccine design.
An immunogenic composition capable of inducing a cytotoxic response in vitro or in vivo against a viral disease through a MHC-1 restricted exogenous antigen presentation pathway without requiring viral replication, containing at least one of the compounds:
A vaccinating composition containing the immunogenic composition according to claim 2 wherein the composition is obtained by the process of claim 16.
A process of treatment of a eukaryotic host suffering from a viral pathology comprising administering a plasmid comprising a polynucleotide coding for the entire or a part of the virus genome and containing an insert containing a polynucleotide coding for a viral envelope (or a part of the envelope or a surface protein), and being under the control of a promoter, said plasmid expressing viral particles being selected for its fusogenic, non-replicative properties, and for inducing a cytotoxic response after a CMH-1 restricted exogenous antigen presentation pathway.
A process of treatment of a eukaryotic host suffering from a viral pathology comprising coadministering a first plasmid comprising the entire or a part of the virus genome and a second plasmid comprising an insert containing a polynucleotide coding for a viral envelope (a part of the envelope or a surface protein) and being under the control of a promoter, said plasmid being selected for its fusogenic properties, and for inducing a cytotoxic response after an exogenous antigen presentation which is MHC-1 restricted.
A method of determining cytotoxic T lymphocyte (CTL) reponse to an antigen, wherein the method comprises:
Dependencies are inferred from the claim text.